UGN-102 +/- TURBT Effective in Newly Diagnosed and Recurrent Low-Grade NMIBC
May 5th 2024A study found that UGN-102, used alone or combined with TURBT, resulted in comparable duration of response and disease-free survival rates in both patients newly diagnosed with and those with recurrent low-grade/intermediate non-muscle invasive bladder cancer.
ADC Choices Require Discretion in HER2-Negative MBC
January 4th 2024As clinicians navigate the array of available antibody-drug conjugates for HER2-negative metastatic breast cancer, Joshua Z. Drago, MD, MS, emphasizes the importance of considering various factors in therapy selection and sequencing.
Zanubrutinib Preferred Over Bendamustine/Rituximas Across CLL/SLL Subgroups
December 15th 2023Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.
Pirtobrutinib Shows Activity in Relapsed/Refractory MCL After Covalent BTK Inhibitor Therapy
December 12th 2023Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.
Longer PFS with Dato-Dxd in HR+/HER2- Inoperable or Metastatic Breast Cancer
December 7th 2023Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
Following Progression on ICIs Lifileucel Shows Anti-tumor Response in Advanced Mucosal Melanoma
October 21st 2023Results of from a subgroup of patients in the phase 2 C-144-01 study with advanced mucosal melanoma showed a clinically meaningful response to lifileucel after progression on immune checkpoint inhibitors.